Literature DB >> 26941493

Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors.

Prabhjot Singh1, Siddharth Yadav1, Sanjay Mahapatra1, Amlesh Seth1.   

Abstract

INTRODUCTION: We aimed to study the outcomes of retroperitoneal lymph node dissection (RPLND) in postchemotherapy residual masses in advanced testicular germ cell tumor (GCT) in the Indian population. PATIENTS AND METHODS: We retrospectively analyzed 35 patients who underwent postchemotherapy RPLND at our institute after primary (29 patients) or salvage (6 patients) chemotherapy over a period of 9 years (June 2003 to July 2012).
RESULTS: The mean age of our patients was 26.8 years. 18 (51.42%) presented with primary tumor in the right testis and 3 (8.51%) had bilateral tumors. Mixed GCT was the most common histology among 19 (54.3%) patients. 14 (40%) patients had the residual mass in para-aortic location, which was the most common site. 14 (40%) patients required an adjunctive procedure, most commonly nephrectomy which was required in 9 out of 14 (25.7%). We recorded 25 complications, mostly Clavien-Dindo grade II. Histopathology of residual mass was necrosis in 17 (48.57%), teratoma in 12 (34.28%), and viable tumor in 6 (17.14%) patients.
CONCLUSION: Nearly half of the patients had either teratoma or viable tumor, thus justifying the surgical resection of postchemotherapy residual mass. Although nearly half of the patients had complications, they were adequately managed and there was no mortality. Thus, postchemotherapy RPLND can be a useful procedure in multimodality approach to GCT in carefully selected patients.

Entities:  

Keywords:  Postchemotherapy; retroperitoneal lymph node dissection (RPLND); testicular tumor

Year:  2016        PMID: 26941493      PMCID: PMC4756548          DOI: 10.4103/0970-1591.173102

Source DB:  PubMed          Journal:  Indian J Urol        ISSN: 0970-1591


  21 in total

1.  Increasing incidence of testicular germ cell tumors among black men in the United States.

Authors:  Katherine A McGlynn; Susan S Devesa; Barry I Graubard; Philip E Castle
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

Review 2.  Role of surgery in management of germ cell tumor.

Authors:  J Sheinfeld; H W Herr
Journal:  Semin Oncol       Date:  1998-04       Impact factor: 4.929

3.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes.

Authors:  P A Nash; I Leibovitch; R S Foster; R Bihrle; R G Rowland; J P Donohue
Journal:  J Urol       Date:  1998-03       Impact factor: 7.450

Review 5.  Guidelines on testicular cancer.

Authors:  Peter Albers; Walter Albrecht; Ferran Algaba; Carsten Bokemeyer; Gabriella Cohn-Cedermark; Alan Horwich; Olbjoern Klepp; M Pilar Laguna; Giorgio Pizzocaro
Journal:  Eur Urol       Date:  2005-07-18       Impact factor: 20.096

6.  Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor.

Authors:  Murilo A Luz; Ahmed F Kotb; Saad Aldousari; Fadi Brimo; Simon Tanguay; Wassim Kassouf; Armen G Aprikian
Journal:  World J Surg Oncol       Date:  2010-11-09       Impact factor: 2.754

7.  Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections.

Authors:  E P Fox; T D Weathers; S D Williams; P J Loehrer; T M Ulbright; J P Donohue; L H Einhorn
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

8.  Complications of post-chemotherapy retroperitoneal lymph node dissection.

Authors:  J Baniel; R S Foster; R G Rowland; R Bihrle; J P Donohue
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

9.  Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.

Authors:  E W Steyerberg; H J Keizer; S D Fosså; D T Sleijfer; G C Toner; H Schraffordt Koops; P F Mulders; J E Messemer; K Ney; J P Donohue
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

10.  2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.

Authors:  Maria De Santis; Alexander Becherer; Carsten Bokemeyer; Franz Stoiber; Karin Oechsle; Franz Sellner; Alois Lang; Kurt Kletter; Bernhard M Dohmen; Christian Dittrich; Jörg Pont
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

View more
  1 in total

1.  Nerve-Sparing Postchemotherapy Retroperitoneal Lymph Node Dissection (PC RPLND) for Nonseminomatous Germ Cell Tumour: Experience from a Tertiary Cancer Centre.

Authors:  Anand Raja; Kanuj Malik; N Kathiresan; Venkatraman Radhakrishnan
Journal:  Indian J Surg Oncol       Date:  2021-03-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.